Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KLTO
stocks logo

KLTO

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Valuation Metrics

The current forward P/E ratio for Klotho Neurosciences Inc (KLTO.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Klotho Neurosciences Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

KLTO News & Events

Events Timeline

(ET)
2025-10-07
18:23:04
Klotho and Turn Let Letter of Intent Lapse
select
2025-09-30 (ET)
2025-09-30
08:36:48
Klotho Neurosciences to purchase specific assets from Turn Biotechnologies
select
2025-08-12 (ET)
2025-08-12
06:03:27
Klotho Neurosciences signs KLTO-202 manufacturing, development agreement
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
11-07PRnewswire
Klotho Neurosciences Wins the 2025 BioTech Breakthrough 'Cell Therapy Innovation of the Year' Award

  • Award Recognition: Klotho Neurosciences, Inc. has won the Fifth Annual BioTech Breakthrough Award for "Cell Therapy Innovation of the Year" for its groundbreaking work in gene and cell therapies targeting neurodegenerative diseases.

  • Innovative Therapies: The company focuses on using a patented form of the human Klotho gene (s-KL) to develop therapies aimed at slowing or reversing diseases like ALS, Alzheimer's, and Parkinson's, addressing the root causes of neuronal aging.

  • Commitment to Patients: CEO Dr. Joseph Sinkule emphasized the importance of developing therapies that improve health span and reduce the burden of age-related diseases, especially as the global population ages.

  • BioTech Breakthrough Awards: The awards program recognizes innovative companies and technologies in the life sciences and biotechnology sectors, celebrating excellence in various fields including biopharma and therapeutics.

[object Object]
Preview
1.0
10-16PRnewswire
Klotho Neurosciences CEO to Attend Longevity Biotech 2025 in Boston

  • Klotho Neurosciences at Longevity Biotech 2025: Klotho Neurosciences, Inc. will participate in the Longevity Biotech 2025 conference in Boston on October 22-23, 2025, engaging with investors and potential partners to discuss advancements in longevity therapeutics.

  • Company Focus and Innovations: The company specializes in developing disease-modifying cell and gene therapies targeting neurodegenerative and age-related disorders, utilizing a patented form of the "anti-aging" Klotho gene and innovative delivery systems.

[object Object]
Preview
8.5
10-08Newsfilter
Klotho Neurosciences Declares Letter of Intent No Longer Valid

  • Klotho's Strategic Decision: Klotho Neurosciences, Inc. has allowed its Letter of Intent with Turn Biotechnologies to expire, as the proposed transaction did not align with the company's long-term strategic goals. The company will instead focus on advancing its anti-aging protein research and treatment development.

  • Market Context and Focus: The longevity medicine market is rapidly growing, driven by an aging global population expected to reach 2.1 billion by 2050. Klotho's research is centered on the human Klotho protein, which is crucial for longevity and aims to address neurodegenerative and age-related disorders.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Klotho Neurosciences Inc (KLTO) stock price today?

The current price of KLTO is 0.49 USD — it has increased 2.94 % in the last trading day.

arrow icon

What is Klotho Neurosciences Inc (KLTO)'s business?

Klotho Neurosciences, Inc. develops essential medicines for the treatment of chronic diseases such as cancer, cardiovascular, and neurodegenerative disorders. The Company's licensed platforms, namely, a generic drug portfolio and a biosimilar biologics platform uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Its primary focus is the advancement of a sustainable portfolio of cell and gene therapy product candidates for age-associated neurologic diseases, both rare orphan diseases and diseases in larger patient populations. The Company's two lead gene therapy product candidates are KLTO-101 (AAV9-CMV-sKL) for the treatment or prevention of Alzheimer’s disease, and KLTO-202 (AAVmyo-Des-sKL) gene therapy product for the treatment and prevention of Lou Gehrig’s disease (amyotrophic lateral sclerosis).

arrow icon

What is the price predicton of KLTO Stock?

Wall Street analysts forecast KLTO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for KLTO is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Klotho Neurosciences Inc (KLTO)'s revenue for the last quarter?

Klotho Neurosciences Inc revenue for the last quarter amounts to -1.85M USD, decreased -35.45 % YoY.

arrow icon

What is Klotho Neurosciences Inc (KLTO)'s earnings per share (EPS) for the last quarter?

Klotho Neurosciences Inc. EPS for the last quarter amounts to USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Klotho Neurosciences Inc (KLTO)'s fundamentals?

The market is revising No Change the revenue expectations for KLTO for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 1.01%.
arrow icon

How many employees does Klotho Neurosciences Inc (KLTO). have?

Klotho Neurosciences Inc (KLTO) has 3 emplpoyees as of December 05 2025.

arrow icon

What is Klotho Neurosciences Inc (KLTO) market cap?

Today KLTO has the market capitalization of 35.54M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free